Stock Analysis
Hypera Third Quarter 2024 Earnings: Misses Expectations
Hypera (BVMF:HYPE3) Third Quarter 2024 Results
Key Financial Results
- Revenue: R$1.92b (down 10% from 3Q 2023).
- Net income: R$376.0m (down 25% from 3Q 2023).
- Profit margin: 20% (down from 23% in 3Q 2023). The decrease in margin was driven by lower revenue.
- EPS: R$0.59 (down from R$0.79 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Hypera Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 18%.
Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Global Pharmaceuticals industry.
Performance of the market in Brazil.
The company's shares are down 1.7% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 2 warning signs for Hypera you should know about.
Valuation is complex, but we're here to simplify it.
Discover if Hypera might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BOVESPA:HYPE3
Hypera
Operates as a pharmaceutical company in Brazil.